To understand the most important priorities of IBD patients who need surgery and quantify the reasons why patients consider delaying surgery, with potential reasons including, but not limited to lack of psychosocial support, gaps in knowledge, social stigma, burden to daily life, financial reasons, concerns about fertility, and mental well-being.

To assess the efficacy, safety, and tolerability of the investigational drug in comparison with placebo in participants with moderately to severely active CD who had inadequate response to or were intolerant of prior biologics.

Primary Objective: Safety and Tolerability

Secondary Objective: Efficacy

The primary goal of this study is to demonstrate the efficacy and safety of brazikumab in participants with moderately to severely active CD and demonstrate the clinical utility of a serum biomarker to identify participants who are most likely to benefit from treatment with brazikumab.

The purpose of this study is to evaluate the efficacy and safety of brazikumab versus placebo to induce clinical remission based on endoscopic improvement, rectal bleeding, and stool frequency scores in participants with moderate to severe UC who have failed or are intolerant to conventional therapy.

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system in adults. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after study treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system in adults. In this study, children and teenagers with moderate to severe Crohn’s Disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after study treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.

To evaluate the efficacy and safety of ozanimod in pediatric participants with moderately to severely active UC.

The purpose of this trial is to:

• To investigate how well the treatment with trial drug BI 706321 (in addition to ustekinumab) can improve the symptoms of CD
• To investigate the safety of BI 706321 and how you tolerate BI 706321
• To collect your blood and assess the amount of BI 706321 in the body (called pharmacokinetics or PK, meaning how your body absorbs and distributes BI 706321 and how BI 706321 leaves the body) and biomarkers (how other proteins in your body are influenced by BI 706321).

To understand important effects of inflammatory bowel disease and its treatments on male reproductive health and fertility